vs
Side-by-side financial comparison of Enphase Energy (ENPH) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($311.4M vs $282.9M, roughly 1.1× Enphase Energy). Bio-Techne runs the higher net margin — 16.4% vs -2.6%, a 19.0% gap on every dollar of revenue. On growth, Bio-Techne posted the faster year-over-year revenue change (-1.5% vs -20.6%). Over the past eight quarters, Bio-Techne's revenue compounded faster (1.3% CAGR vs -3.4%).
Enphase Energy, Inc. is an American energy technology company headquartered in Fremont, California, that develops and manufactures solar micro-inverters, battery energy storage, and EV charging stations primarily for residential customers. Enphase was established in 2006 and is the first company to successfully commercialize solar micro-inverters, which convert the direct current (DC) power generated by solar panels into grid-compatible alternating current (AC) for use or export.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
ENPH vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $282.9M | $311.4M |
| Net Profit | $-7.4M | $51.0M |
| Gross Margin | 35.5% | 66.9% |
| Operating Margin | 54.0% | 24.2% |
| Net Margin | -2.6% | 16.4% |
| Revenue YoY | -20.6% | -1.5% |
| Net Profit YoY | -124.9% | 126.0% |
| EPS (diluted) | $-0.06 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $282.9M | $311.4M | ||
| Q4 25 | $343.3M | $295.9M | ||
| Q3 25 | $410.4M | — | ||
| Q2 25 | $363.2M | $317.0M | ||
| Q1 25 | $356.1M | $316.2M | ||
| Q4 24 | $382.7M | $297.0M | ||
| Q3 24 | $380.9M | $289.5M | ||
| Q2 24 | $303.5M | $306.1M |
| Q1 26 | $-7.4M | $51.0M | ||
| Q4 25 | $38.7M | $38.0M | ||
| Q3 25 | $66.6M | — | ||
| Q2 25 | $37.1M | $-17.7M | ||
| Q1 25 | $29.7M | $22.6M | ||
| Q4 24 | $62.2M | $34.9M | ||
| Q3 24 | $45.8M | $33.6M | ||
| Q2 24 | $10.8M | $40.6M |
| Q1 26 | 35.5% | 66.9% | ||
| Q4 25 | 44.3% | 64.6% | ||
| Q3 25 | 47.8% | — | ||
| Q2 25 | 46.9% | 62.7% | ||
| Q1 25 | 47.2% | 67.9% | ||
| Q4 24 | 51.8% | 65.3% | ||
| Q3 24 | 46.8% | 63.2% | ||
| Q2 24 | 45.2% | 66.4% |
| Q1 26 | 54.0% | 24.2% | ||
| Q4 25 | 6.5% | 18.4% | ||
| Q3 25 | 16.1% | — | ||
| Q2 25 | 10.2% | -7.5% | ||
| Q1 25 | 9.0% | 12.2% | ||
| Q4 24 | 14.3% | 16.0% | ||
| Q3 24 | 13.1% | 13.8% | ||
| Q2 24 | 0.6% | 15.0% |
| Q1 26 | -2.6% | 16.4% | ||
| Q4 25 | 11.3% | 12.8% | ||
| Q3 25 | 16.2% | — | ||
| Q2 25 | 10.2% | -5.6% | ||
| Q1 25 | 8.3% | 7.1% | ||
| Q4 24 | 16.2% | 11.7% | ||
| Q3 24 | 12.0% | 11.6% | ||
| Q2 24 | 3.6% | 13.3% |
| Q1 26 | $-0.06 | $0.32 | ||
| Q4 25 | $0.29 | $0.24 | ||
| Q3 25 | $0.50 | — | ||
| Q2 25 | $0.28 | $-0.11 | ||
| Q1 25 | $0.22 | $0.14 | ||
| Q4 24 | $0.46 | $0.22 | ||
| Q3 24 | $0.33 | $0.21 | ||
| Q2 24 | $0.08 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.5M | $209.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $2.1B |
| Total Assets | $2.7B | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $497.5M | $209.8M | ||
| Q4 25 | $1.5B | $172.9M | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | $162.2M | ||
| Q1 25 | $1.5B | $140.7M | ||
| Q4 24 | $1.6B | $177.5M | ||
| Q3 24 | $1.8B | $187.5M | ||
| Q2 24 | $1.6B | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | $260.0M | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | $346.0M | ||
| Q1 25 | $1.2B | $330.0M | ||
| Q4 24 | $1.3B | $300.0M | ||
| Q3 24 | $1.3B | $300.0M | ||
| Q2 24 | $1.3B | $319.0M |
| Q1 26 | $1.1B | $2.1B | ||
| Q4 25 | $1.1B | $2.0B | ||
| Q3 25 | $995.0M | — | ||
| Q2 25 | $880.6M | $1.9B | ||
| Q1 25 | $810.7M | $2.0B | ||
| Q4 24 | $833.0M | $2.1B | ||
| Q3 24 | $931.4M | $2.1B | ||
| Q2 24 | $884.5M | $2.1B |
| Q1 26 | $2.7B | $2.6B | ||
| Q4 25 | $3.5B | $2.5B | ||
| Q3 25 | $3.3B | — | ||
| Q2 25 | $3.2B | $2.6B | ||
| Q1 25 | $3.1B | $2.6B | ||
| Q4 24 | $3.2B | $2.7B | ||
| Q3 24 | $3.3B | $2.7B | ||
| Q2 24 | $3.2B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | 1.11× | 0.13× | ||
| Q3 25 | 1.21× | — | ||
| Q2 25 | 1.37× | 0.18× | ||
| Q1 25 | 1.48× | 0.16× | ||
| Q4 24 | 1.56× | 0.14× | ||
| Q3 24 | 1.40× | 0.14× | ||
| Q2 24 | 1.47× | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $102.9M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $102.9M | — | ||
| Q4 25 | $47.6M | — | ||
| Q3 25 | $13.9M | — | ||
| Q2 25 | $26.6M | $98.2M | ||
| Q1 25 | $48.4M | $41.1M | ||
| Q4 24 | $167.3M | $84.3M | ||
| Q3 24 | $170.1M | $63.9M | ||
| Q2 24 | $127.1M | $75.5M |
| Q1 26 | — | — | ||
| Q4 25 | $37.8M | — | ||
| Q3 25 | $5.9M | — | ||
| Q2 25 | $18.4M | $93.3M | ||
| Q1 25 | $33.8M | $31.0M | ||
| Q4 24 | $159.2M | $77.5M | ||
| Q3 24 | $161.6M | $54.7M | ||
| Q2 24 | $117.4M | $57.5M |
| Q1 26 | — | — | ||
| Q4 25 | 11.0% | — | ||
| Q3 25 | 1.4% | — | ||
| Q2 25 | 5.1% | 29.4% | ||
| Q1 25 | 9.5% | 9.8% | ||
| Q4 24 | 41.6% | 26.1% | ||
| Q3 24 | 42.4% | 18.9% | ||
| Q2 24 | 38.7% | 18.8% |
| Q1 26 | — | — | ||
| Q4 25 | 2.8% | — | ||
| Q3 25 | 2.0% | — | ||
| Q2 25 | 2.3% | 1.5% | ||
| Q1 25 | 4.1% | 3.2% | ||
| Q4 24 | 2.1% | 2.3% | ||
| Q3 24 | 2.2% | 3.2% | ||
| Q2 24 | 3.2% | 5.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.23× | — | ||
| Q3 25 | 0.21× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 1.63× | 1.82× | ||
| Q4 24 | 2.69× | 2.42× | ||
| Q3 24 | 3.72× | 1.90× | ||
| Q2 24 | 11.73× | 1.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ENPH
Segment breakdown not available.
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
